Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome

Surgery

Volumn 146, Issue 2, 2009, Pages 220-226

  Flowers, Anthony ^b   Chu, Quyen D ^a   Panu, Lori ^b   Meschonat, Carol ^a   Caldito, Gloria ^b   Lowery Nordberg, Mary ^b   Li, Benjamin D L ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 67650517119     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.05.010     Document Type: Article

References (24)

1. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
2. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumors. Nature 406 (2000) 747-752
3. Kang S., Martel M., and Harris L. Triple-negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20 (2008) 40-46
4. Reis-Filho J.S., and Tutt A.N.J. Triple negative tumours: a critical review. Histopathology 52 (2008) 108-118
5. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
6. Li B.D.L., Liu L., Dawson M., and De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79 (1997) 2385-2390
7. Li B.D.L., McDonald J.C., Nassar R., and De Benedetti A. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227 (1998) 756-763
8. Li B.D.L., Gruner J.S., Abreo F., Johnson L.W., Yu H., Nawas S., et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235 (2002) 732-739
9. Sorrells D.L., Meschonat C., Black D., and Li B.D.L. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. J Surg Res 85 (1999) 37-42
10. Kevil C.G., De Benedetti A., Payne D.K., Coe L.L., Laroux F.S., and Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 65 (1996) 785-790
11. Byrnes K., White S., Chu Q., Meschonat C., Yu H., Johnson L.W., et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243 (2006) 684-692
12. Norton K.S., McClusky D., Sen S., Yu H., Meschonat C., Debenedetti A., et al. TLK1B is elevated with eIF4E overexpression in breast cancer. J Surg Res 116 (2004) 98-103
13. Li Y., DeFatta R., Anthony C., Sunavala G., and De Benedetti A. A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 20 (2001) 726-738
14. Shalom S., and Don J. Tlk, a novel evolutionarily conserved murine serine threonine kinase, encodes multiple testis transcripts. Mol Reprod Dev 52 (1999) 392-405
15. American Joint Committee on Cancer Breast. Handbook for staging of cancer, from the manual for staging of cancer. In: Beahrs O.H., Henson D.E., Hutter R.V.P., and Kennedy B.J. (Eds). Handbook for staging of cancer, from the manual for staging of cancer. 4th edition (1993), J.B. Lippincott, Philadelphia 161-167
16. Kerekatte V., Smiley K., Hu B., Smith A., Gelder F., and De Benedetti A. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 64 (1995) 27-31
17. Holm N., Byrnes K., Johnson L., Abreo F., Sehon K., Alley J., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer. Ann Surg Oncol 15 (2008) 3207-3215
18. McClusky D.R., Chu Q., Yu H., De Benedetti A., Johnson L.W., Meschonat C., et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 242 (2005) 584-590
19. Wolfort R., De Benedetti A., Nuthalapaty S., Yu H., Chu Q.D., and Li B.D. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 140 (2006) 161-169
20. Byrnes K.W., De Benedetti A., Holm N.T., Luke J., Nunez J., Chu Q.D., et al. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression. J Am Coll Surg 204 (2007) 925-933
21. Kwak Y.D., Koike H., and Sugaya K. RNA interference with small hairpin RNAs transcribed from a human U6 promoterdriven DNA vector. Pharmacol Sci 93 (2003) 214-217
22. Rosenwald I., Lazaris-Karatzas A., Sonenberg N., and Schmidt E. Elevated levels of cyclin D1 in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 13 (1993) 7358-7363
23. Rousseau D., Kaspar R., Rosenwald I., Gehrke L., and Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 93 (1996) 1065-1070
24. Dong K., Wang R., Wang X., Lin F., Shen J.J., Gao P., et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 113 (2009) 443-456